Literature DB >> 2288838

Use of Emax model in diuretic studies.

F H Noormohamed.   

Abstract

Mesh:

Substances:

Year:  1990        PMID: 2288838      PMCID: PMC1368315          DOI: 10.1111/j.1365-2125.1990.tb05460.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Semiparametric approach to pharmacokinetic-pharmacodynamic data.

Authors:  D Verotta; S L Beal; L B Sheiner
Journal:  Am J Physiol       Date:  1989-04

2.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

3.  The time course of delivery of furosemide into urine: an independent determinant of overall response.

Authors:  S Kaojarern; B Day; D C Brater
Journal:  Kidney Int       Date:  1982-07       Impact factor: 10.612

4.  Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling.

Authors:  M M Hammarlund; B Odlind; L K Paalzow
Journal:  J Pharmacol Exp Ther       Date:  1985-05       Impact factor: 4.030

5.  Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide.

Authors:  M G Lee; T Li; W L Chiou
Journal:  Biopharm Drug Dispos       Date:  1986 Nov-Dec       Impact factor: 1.627

6.  Diuretic effect and diuretic efficiency after intravenous dosage of frusemide.

Authors:  G Alván; L Helleday; A Lindholm; E Sanz; T Villén
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

  6 in total
  2 in total

1.  The validity of the sigmoid Emax model and efficiency concept in diuretic studies.

Authors:  G Alván; M Hammarlund-Udenaes; B Odlind
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.

Authors:  G Alván; G Paintaud; S A Eckernäs; A Grahnén
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.